Systemic candidiasis is an important complication in neutropenic patients and those undergoing treatment for cancer ([@B1]). This infection has increased persistently over the past three decades and represents a significant cause of morbidity and mortality among high risk individuals ([@B2]). The predisposing factors for systemic candidiasis in neutropenic patients with hematological malignancies differ according to the level of immune suppression and role of the underlying neoplastic process ([@B3], [@B4]). Neutropenia may initiate due to radiation, bone marrow failure (aplastic anemia and myelodysplasia), chemotherapy, and replacement of hematopoietic cells by malignant cells in the bone marrow ([@B3], [@B5]). The digestive tract is the main entrance of *Candida* species in patients with acute neutropenia and leukemia and a region of endogenous microflora. Invasion of *Candida* to bloodstream may occur through disruption of the normal anatomical barriers. *Candida* infections may present as oropharyngeal candidiasis, esophagitis, candidemia, acute or chronic disseminated candidiasis among this population ([@B4], [@B6], [@B7]). The aim of the present study was to identify *Candida* species isolated from the different regions of body in neutropenic patients in compare with the control group. Due to the different susceptibilities of the conventional antifungal drugs such as fluconazole and itraconazole, timely and precise identification of *Candida* spp. would be noteworthy for successful treatment of the infection.

Methods
=======

**Isolates:**From March 2014 to August 2015, a total of 309 neutropenic patients with suspected candidiasis from two university hospitals were included in the present study. In addition, we provided a control group without cancer comprised of 584 concurrent hospitalized patients in the ICU (274 patients), transplantation ward (169 patients), and general medicine ward (141 patients) who had no any cancer or cancer history. After sampling, all specimens were examined by direct microscopic examination (DM) with 10% potassium hydroxide (KOH), and culture on sabouraud glucose agar (Difco, Detroit, MI, USA), and CHROMagar Candida (Paris, France).

**Molecular identification**

**DNA extraction:**The genomic DNA of all isolates was extracted using FTA ® Elute MicroCards (Whatman Inc., Clifton, NJ, USA) ([@B8]), following the manufacturer\'s instructions. Briefly, a loopful of a single colony was suspended in 80-100 μl of distilled water and 5 μl of the suspension was transferred to a disc of FTA card (4 mm in diameter) and incubated at 25°C for at least 5 h. The dried papers were eluted in 400 μl sterile water for 10 seconds, then the paper was transferred to a new microtube containing 40 μl distilled water and incubated at 95 ° C for 15 min. The paper discs were removed and the water including DNA was used for PCR and stored at - 20 °C.

**Polymerase chain reaction (PCR):**Identification of *Candida* spp. was performed using the already delineated PCR-RFLP profiles ([@B9]-[@B11]). Briefly, the ITS1-5.8SrDNA-ITS2 region was amplified using PCR mixture including 5μl of 10 × reaction buffer, 0.4 mM dNTPs, 1.5 mM MgCl2, 2.5 U of Taq polymerase, 30 pmol of both ITS1 (5′ -TCC GTA GGT GAA CCT GCG G-3′) and ITS4 (5′ -TCC TCC GCT TAT TGA TAT GC-3′) primers ([@B10]), and 2μl of extracted DNA in a final volume of 50μl. The PCR cycling conditions comprised: initial denaturation at 94 ° C for 5 min, followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 45 s, and extension at 72 ° C for 1 min, with a final extension at 72 °C for 7 min.

**Restriction fragment length polymorphism (RFLP):**During the second step, PCR products were digested with the restriction enzyme *Hpa*II (Fermentas, Vilnius, Lithuania).

**Electrophoresis:** Five microliters of each PCR amplicons and 10μl of RFLP products were separated by gel electrophoresis on 1.5 and 2% agarose gel (containing 0.5 μg/ml ethidium bromide), respectively.

**Statistical Analysis:**Data were analyzed using the SPSS software Version 17.0. Prevalence and types of *Candida* infection and their distribution were compared according to sex and age in patients and control group. Chi square and Independent sample t-test were used for analyses. A P-value of \< 0.05 was considered significant.

Results
=======

Twenty-two out of 309 patients had candidiasis (7.1%). Age range of patients was between 23 and 66 years (mean age, 44.5 years). Male to female ratio was 1/1. Colorectal cancer and acute myeloid leukemia (AML) were the most common cancers accounted for 50% of all cases. Cancer patients included 63.6% with organ and 36.4% with hematological malignancies. Clinical specimens were obtained from urine (59.1%), blood (18.2%), skin lesion (13.6%), soft tissue abscess (4.5%), and abdominal abscess (4.5%). The patients had been hospitalized in haematology ward (59.1%), and ICU (40.9%). *Candida albicans* was the most prevalent species (50%) followed by *C. glabrata* (36.3%), and *C. tropicalis* (13.6%) ([fig1](#F1){ref-type="fig"}).

![Agarose gel electrophoresis of ITS-PCR products of various *Candida* species after digestion with *Hpa*II. Lanes 1,3,6,8 are *C. albicans*, and Lanes 2, 4, 5, 7, 9 are *C. glabrata*, and Lane M: 100 bp DNA size marker](cjim-7-071-g001){#F1}

[Table 1](#T1){ref-type="table"} summarizes the characteristics of all study patients. In the control group, 19 out of 584 patients (3.2%) were infected to different forms of candidiasis ([Table 2](#T2){ref-type="table"}). The mean age of patients in the control group was 35.4 years. In this group, *Candida albicans* was also the most common specie (57.9%) followed by *C. parapsilosis* (21%). There was no case with *C. tropicalis* infection among *Candida*strains isolated from the control group.

###### 

Details of neutropenic patient with candidiasis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **No**   **Sex**   **Age**   **Hospital wards**   **Alive/ Deceased**   **Cancer of**         **Signs**                                    **Location body**     **WBC count (/µl)**   **Neutrophil**\   **Neutrophil (%)**   ***Candida*** **spp.**
                                                                                                                                                                                         **(/µl)**                              
  -------- --------- --------- -------------------- --------------------- --------------------- -------------------------------------------- --------------------- --------------------- ----------------- -------------------- ------------------------
  1        F         27        Haematology          Alive                 Breast                Breast lumps                                 Urine                 1650                  800               48                   *C. albicans*

  2        M         39        ICU                  Alive                 AML                   Weakness                                     Blood                 2050                  760               37                   *C. glabrata*

  3        M         57        Haematology          Alive                 Lung                  Cough, Sputum                                Urine                 2300                  950               41                   *C. albicans*

  4        M         61        Haematology          Alive                 Colon                 Gastrointestinal bleeding                    Urine                 1400                  670               47                   *C. glabrata*

  5        F         40        ICU                  Alive                 Osteosarcoma          Pain in the lower femur                      Urine                 2700                  1150              42                   *C. albicans*

  6        F         34        ICU                  Deceased              AML                   Weakness                                     Blood                 900                   460               51                   *C. albicans*

  7        F         42        ICU                  Alive                 Colon                 Gastrointestinal bleeding                    Blood                 3400                  1200              35                   *C. albicans*

  8        F         61        Haematology          Alive                 Colon                 Gastrointestinal bleeding                    Urine                 1400                  540               33                   *C. albicans*

  9        F         54        Haematology          Alive                 Breast                Breast lumps                                 Urine                 2150                  1200              55                   *C. albicans*

  10       M         30        Haematology          Alive                 Colon                 Gastrointestinal bleeding, Constipation      Urine                 1300                  670               51                   *C. glabrata*

  11       F         43        Haematology          Alive                 Hodgkin\'s lymphoma   Lymphadenopathy                              Skin lesion           2400                  1100              45                   *C. tropicalis*

  12       M         51        ICU                  Alive                 Colon                 Gastrointestinal bleeding                    Soft tissue abscess   1080                  540               50                   *C. glabrata*

  13       M         47        ICU                  Deceased              Pancreas              Abdominal lumps                              Abdominal abscess     1800                  920               51                   *C. glabrata*

  14       M         24        Haematology          Alive                 Multiple myeloma      Pain in the bones                            Urine                 1300                  450               34                   *C. glabrata*

  15       F         31        Haematology          Alive                 AML                   Weakness                                     Skin lesion           3100                  1050              33                   *C. tropicalis*

  16       F         54        Haematology          Alive                 Stomach               Gastrointestinal bleeding, Abdominal pains   Urine                 1700                  840               49                   *C. albicans*

  17       M         23        ICU                  Alive                 Esophagus             Dysphagia                                    Urine                 2050                  900               43                   *C. tropicalis*

  18       M         62        Haematology          Alive                 Colon                 Gastrointestinal bleeding                    Urine                 2700                  1100              40                   *C. albicans*

  19       F         43        ICU                  Deceased              AML                   Weakness                                     Blood                 1400                  650               46                   *C. glabrata*

  20       M         40        Haematology          Alive                 AML                   Asymptomatic                                 Urine                 2350                  1200              51                   *C. albicans*

  21       F         66        Haematology          Alive                 Hodgkin\'s lymphoma   Lymphadenopathy, Abdominal pains             Skin lesion           1900                  740               38                   *C. albicans*

  22       M         50        ICU                  Alive                 Lung                  Hemoptysis                                   Urine                 2100                  800               38                   *C. glabrata*
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Control group in the present study; patients with different forms of candidiasis without cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **No**   **Sex**   **Age**   **Hospital wards**    **Alive/ Deceased**   **Clinical site**   **Signs**                **WBC count (/µl)**   **Neutrophil**\   **Neutrophil (%)**   ***Candida*** **spp.**
                                                                                                                                              **(/µl)**                              
  -------- --------- --------- --------------------- --------------------- ------------------- ------------------------ --------------------- ----------------- -------------------- ------------------------
  1        F         5         ICU                   Alive                 Blood               Fever                    15300                 10863             71                   *C. albicans*

  2        F         26        ICU                   Alive                 Blood               Fever, Pain of joints    13400                 9246              69                   *C. albicans*

  3        F         18        Transplantaion Ward   Alive                 Urine               Painful urination        6600                  4554              69                   *C. parapsilosis*

  4        M         55        Transplantaion Ward   Alive                 Urine               Fever and chills         8100                  3969              49                   *C. albicans*

  5        F         63        ICU                   Alive                 Blood               Fever and chills         16900                 9800              58                   *C. albicans*

  6        F         49        ICU                   Deceased              Blood               Fever                    19400                 15520             80                   *C. albicans*

  7        F         38        General ward          Alive                 Vulvovagina         Vulvovaginal discharge   10500                 5670              54                   *C. parapsilosis*

  8        F         11        Transplantaion Ward   Alive                 Blood               Pain and tenderness      9100                  6825              75                   *C. albicans*

  9        M         27        ICU                   Alive                 Blood               Fever                    14000                 9940              71                   *C. albicans*

  10       M         39        ICU                   Alive                 Skin lesion         Inflammatory, Pruritus   8200                  5330              65                   *C. parapsilosis*

  11       F         41        Transplantaion Ward   Alive                 Urine               Fever and chills         9450                  6140              65                   *C. albicans*

  12       M         17        ICU                   Alive                 Catheter            Fever                    21000                 11130             53                   *C. albicans*

  13       M         14        ICU                   Alive                 Blood               Fever                    11700                 8892              76                   *C. albicans*

  14       M         55        ICU                   Alive                 BAL                 Cough, Chest pain        11050                 6630              60                   *C. krusei*

  15       F         69        Transplantaion Ward   Alive                 Blood               Fever                    14900                 10280             69                   *C. albicans*

  16       M         27        General ward          Alive                 Urine               Fever                    8800                  5016              57                   *C. kefyr*

  17       F         20        General ward          Alive                 Skin lesion         Pruritus                 7600                  5320              70                   *C. glabrata*

  18       F         48        General ward          Alive                 Urine               Asymptomatic             12650                 7843              62                   *C. parapsilosis*

  19       F         51        ICU                   Alive                 Perleche            Pruritus                 6550                  4322              65                   *C. glabrata*
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Twelve patients (63.1%) were females and 7 control patients (36.8%) were males, age ranging from 5 to 69 years. Surprisingly, all *Candida* species that were isolated from blood stream were *C. albicans*. Mortality rate in cancer patients (13.6%) was significantly higher than the control group (5.2%).

*Candida* infection in cancer patients was greater than the control group \[OR (CI 95%): 2.28 (1.21-4.28%), P=0.009\] ([table 3](#T3){ref-type="table"}).

###### 

Statistical analysis of candidosis among neutropenic patients and control group

  -------------------------------------------------------------------------
  **Factors**        **Cancer(n=309)**   **Control(n=584)**   **P value**
  ------------------ ------------------- -------------------- -------------
  Age(year)          44.50±12.91         35.42±18.83          0.076^□^

  **Sex**\           11(50.0%)\          7(36.8%)\            0.397□
  Male\              11(50.0%)           12(63.2%)            
  Female                                                      

  **Candidiasis**\   22(7.1%)\           19(3.3%)\            0.009□
  Yes\               287(92.9%)          565(96.7%)           
  No                                                          
  -------------------------------------------------------------------------

Data Showed Mean±SD and n(%),: Used of Independent sample t test, : Used of Chi-Square

Discussion
==========

Most fatal *Candida*infections result from endogenous host microbiota ([@B9], [@B10]). Colonization due to the non-*Candida albicans* spp. is increasing ([@B2], [@B11], [@B12]), and in recent years significant increase in frequency of blood stream isolated infection has been reported in particular *Candida* infection due to *C. krusei, C. tropicalis* and *C. glabrata* in high risk population, like patients with neutropenia is of serious concern. In the present study, we also isolated 2 out of 4 (50%) *C. glabrata* from cancer patients with candidemia.

However, no *C. glabrata* strain was isolated from the bloodstream infection in the control group. The intestinal tract is the main source for hematogenous *Candida* invasion ([@B13]-[@B15]). Mortality rate was 13.6% and 5.2% in neutropenic patients and control group, respectively. As expected, mortality rate in patients with candidemia was the highest in both groups. There has been a crucial shift in the causes of blood stream *Candida* infection from *C. albicans* toward non-*albicans Candida* species in neutropenic patients ([@B4]), but *C. albicans* was the most prevalent strain isolated from candidemia in the control group. Candidemia in neutropenic patients may be complicated by chronic disseminated candidiasis of eyes, spleen, liver, kidney, and abdomen ([@B16]). We also showed two patients (9.1%) with soft tissue abscess, and abdominal abscess as a result of chronic disseminated candidiasis.

Among the patients with candiduria, 7 patients (53.8%) had lower urinary tract symptoms (LUTS) (such as painful urination, increased frequency of urination, and incomplete voiding), 2 patients (15.4%) had upper urinary tract symptoms (UUTS) (including fever, chills, pain and tenderness, nausea, and vomiting), and 4 (30.7%) cases were asymptomatic, compared to the control group that 2 patients (40%) had UUTS, 2 patients (40%) with LUTS, and 1 patient (20%) was asymptomatic.

The prevalence of candiduria is associated with antibiotic use ([@B17]), and varies in different hospital wards, being most prevalent in intensive care units (ICUs) ([@B18]) however, in the present study, only two patients with candiduria were hospitalized in ICU (in cancer patients) and also none of the patients in control group with candiduria hospitalized in ICU. Some studies showed that a low percentage (1-8%) of candiduric patients presents candidemia ([@B19]-[@B21]), however patients with candiduria in the present investigation did not shift toward bloodstream *Candida* infection except a patient undergoing kidney transplantation in the control group. In contrast to our findings, in many investigations *C. parapsilosis* complex was the main *Candida* species that is associated with candidiasis, containing candiduria ([@B22]-[@B24]), nevertheless, we did not isolate any *C. parapsilosis* complex from neutropenic patient whereas, 4 cases of *C. parapsilosis* (21%) isolates were identified in the control group. Afraseyabi et al. ([@B25]) isolated 19 *Candida* spp. from 60 cancer patients (31.6%). They reported gastrointestinal and breast cancer as the most frequent cancer whereas, colorectal cancer and acute myeloid leukemia (AML) were the most common cancers in the present study. Shokohi et al. ([@B26]) reported *Candida albicans* as the most common species among 80 neutropenic patients with candidosis (77.5%), followed by *C.glabrata* (15%), *C. tropicalis* (5%) and *C. krusei* (2.5%). Saltanatpouri et al. ([@B27]) reported *C.albicans* as the most prevalent *Candida* strain isolated from candidiasis in cancer patients. Brain tumor and esophageal cancer were the most frequent cancers in their investigation. Of the 68 blood samples collected from cancer patients, Kalantar et al. ([@B28]) showed that five (7.35%) were positive for *Candida* spp., 2 (40%) of which were identified as *C. albicans* and 3 (60%) were *Candida* non-*albicans*.

In conclusion, neutropenic population which has noticeable colonization with *Candida* spp particularly in different parts of the body and presence of *C. glabrata*, *C. tropicalis* or *C. krusei* should be considered as higher risk of mortality. Administration of fluconazole seems to be reasonable in preventing candidiasis due to *C. albicans* in neutopenic patients, but strategies to decrease *Candida* infections by nontriazole susceptible to *Candida*species like *C. glabrata* are unreliable. Due to the fact that candidiasis is connected with high morbidity and mortality rate among neutropenic patients, and emerging of antifungal resistance among *Candida* isolates, epidemiological data and susceptibility patterns of colonized *Candida* species may be useful for clinicians to select the best therapeutic choice for the management of infection among high-risk cases.
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